Healthcare Services

Neurogenetic Testing Market Forecast 2026–2035 Reflecting Expansion Opportunities Across Industries

April 3, 2026April 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Neurogenetic Testing Market By The End Of 2030?

The neurogenetic testing market has seen a rapid increase in its size over recent years. It is projected to expand from $0.7 billion in 2025 to $0.79 billion in 2026, driven by a compound annual growth rate (CAGR) of 13.5%. This historical growth can be attributed to several factors, including the early adoption of pcr-based genetic testing, the rising prevalence of inherited neurological disorders, the increased use of microarray platforms, the development of early diagnostic techniques, and the initial integration of genetic screening into clinical workflows.

The neurogenetic testing market is anticipated to experience significant expansion in the coming years. This market is projected to reach a size of $1.24 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.9%. This growth during the forecast period is primarily driven by factors such as the increasing demand for next-generation sequencing, the expanding use of clinical exome sequencing, greater investment in genetic research, the creation of advanced molecular diagnostic tools, and the increasing acceptance of personalized neurological treatment methods. Key trends anticipated during this period encompass the increasing integration of whole-exome sequencing technologies, the growing application of PCR-based neurological genetic tests, broader implementation of microarray analysis, the expansion of testing services for rare neurological genetic disorders, and a rising demand for early diagnosis and predictive testing capabilities.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16131&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Neurogenetic Testing Market?

An increase in the occurrence of neurological disorders is anticipated to stimulate the expansion of the neurogenetic testing market. These disorders encompass various conditions impacting the nervous system, including the brain, spinal cord, and nerves. Their widespread presence is often attributed to genetic predispositions, infections, trauma, exposure to toxins, autoimmune reactions, and degenerative processes. Neurogenetic testing plays a crucial role in improving the diagnosis, treatment, and overall management of neurological disorders. It achieves this by providing individualized information on genetic risk factors, informing therapeutic choices, and enabling patients and their families to make well-informed healthcare decisions, ultimately leading to better patient care and results. For example, data from October 2023, released by the World Federation of Neurology, a UK-based charity, indicates the increasing global health burden. Neurological disorders are now the second-leading cause of death and the leading cause of disability globally. More than 40 percent of the world’s population was affected in 2023, and the number of people living with brain disease is expected to almost double by 2050. Consequently, the growing prevalence of neurological disorders is anticipated to fuel the expansion of the neurogenetic testing market.

Which Segment Classifications Shape The Neurogenetic Testing Market?

The neurogenetic testing market covered in this report is segmented –

1) By Type: Microarray Analysis, Whole-Exome Sequencing (WES), Multiplex Ligation Dependent Probe Amplification (MLPA), Polymerase Chain Reaction (PCR) Tests, Other Types

2) By Disease: Rare Genetic Disorder, Huntington’s Disease, Fragile X Syndrome, Other Diseases

3) By End-Users: Hospitals, Specialty Clinics, Research Institutes, Diagnostics Laboratories

Subsegments:

1) By Microarray Analysis: Comparative Genomic Hybridization (CGH) Microarray, Single Nucleotide Polymorphism (SNP) Microarray, Gene Expression Microarray

2) By Whole-Exome Sequencing (WES): Targeted Exome Sequencing, Clinical Exome Sequencing, Research-Grade Exome Sequencing

3) By Multiplex Ligation Dependent Probe Amplification (MLPA): MLPA For Copy Number Variation, MLPA For Methylation Analysis, MLPA For Specific Disease Detection

4) By Polymerase Chain Reaction (PCR) Tests: Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR (dPCR)

5) By Other Types: Next-Generation Sequencing (NGS), Southern Blotting, Fluorescence In Situ Hybridization (FISH), Sanger Sequencing

Which Trends Are Shaping The Future Of The Neurogenetic Testing Market?

Major companies in the neurogenetic testing market are developing innovative products, such as whole-genome sequencing, to enhance the accuracy and scope of genetic analysis, facilitating more comprehensive and personalized testing for neurological disorders. Whole-genome sequencing (WGS) is an extensive genetic testing method that involves determining the complete DNA sequence of an individual’s entire genome. For instance, in March 2024, Nucleus Genomics, a US-based company providing genetic analysis, introduced a DNA analysis product. Through this platform, individuals gain a deeper understanding of their genetic predispositions, enabling informed decisions about their health and well-being. With cutting-edge technology and expert genetic counseling services, Nucleus Genomics is poised to redefine the genetic testing landscape, bringing the power of whole-genome sequencing directly to individuals and revolutionizing the field of genomic medicine.

Which Companies Are Expanding Their Footprint In The Neurogenetic Testing Market?

Major companies operating in the neurogenetic testing market are Thermo Fisher Scientific Inc., Mayo Clinic, Roche Diagnostics Corporation, Laboratory Corporation, Quest Diagnostics Incorporated, Eurofins Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Myriad Genetics Inc., BioReference Laboratories Inc., Connecticut Children’s, Invitae Corp., Ambry Genetics Corporation, Fulgent Genetics Inc., Blueprint Genetics Inc., GeneDx LLC, Pacific Biosciences of California Inc., MedGenome Labs, CENTOGENE, Baylor Genetics, Victorian Clinical Genetics Services

Read the full neurogenetic testing market report here:

https://www.thebusinessresearchcompany.com/report/neurogenetic-testing-global-market-report

Which Regions Are Projected To Dominate The Neurogenetic Testing Market In The Coming Years?

North America was the largest region in the neurogenetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neurogenetic Testing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16131&type=smp

Browse Through More Reports Similar to the Global Neurogenetic Testing Market 2026, By The Business Research Company

Idiopathic Pulmonary Fibrosis Global Market Report

https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report

Rare Neurological Disease Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Acoustic Neuroma Global Market Report

https://www.thebusinessresearchcompany.com/report/acoustic-neuroma-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795